The researchers have emerged with the discovery that CBG, a cannabinoid, does not leave adverse effects on the behavior of users and, at the same time, it has potential to cure cancerous diseases. Besides preventing the reuptake of endocannabinoids, it serves to stimulate the channels for TRPA1 (Transient Receptor Potential A1), TRPV1 and TRPV2. At the same time, the CBG compound has capacity to block the channel for TRP M8. Through the beneficial effects of this cannabinoid, the symptoms of irritable bowel syndrome and glaucoma can be relieved.
A recent study conducted by the NIH (National Institute of Health) revealed that CBG can play an effective role in the treatment of colon cancer by preventing or slowing down the further progress of the disease. Carcinogenesis, the Oxford journal, published these revolutionary findings.
The aim of the research on this cannabinoid is to find out whether it can provide protection against tumorigenesis in colon of the patient. While experimenting on the effectiveness of CBG in colon cancer, the medical researchers discovered that in real life situations it can prevent the progress of chemically-induced colon carcinogenesis as well as xenograft tumors. Based on the findings of the study, CBG can selectively prevent the progress of cells in colorectal cancer and retard the growth of colon cancer.
To sum up the research findings, CBG can be regarded as one of the potential measures for the prevention as well as cure of colorectal cancer.
A survey by the ACS (American Cancer Society) says that, in 2014 alone, more than fifty thousand individuals died of colorectal cancer in the United States. This type of cancerous disorder has become the third most common cancer, victimizing people in the US. However, it is to be noted that for the last 20 years, the death toll caused by colorectal cancer has been on decrease. The development and application of the colorectal screening techniques has contributed a great deal in reducing death rate.